HRP20230243T1 - Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze - Google Patents

Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze Download PDF

Info

Publication number
HRP20230243T1
HRP20230243T1 HRP20230243TT HRP20230243T HRP20230243T1 HR P20230243 T1 HRP20230243 T1 HR P20230243T1 HR P20230243T T HRP20230243T T HR P20230243TT HR P20230243 T HRP20230243 T HR P20230243T HR P20230243 T1 HRP20230243 T1 HR P20230243T1
Authority
HR
Croatia
Prior art keywords
alkylene
difluoromethoxy
isopropylphenyl
methylpyridin
alkyl
Prior art date
Application number
HRP20230243TT
Other languages
English (en)
Croatian (hr)
Inventor
Martin Bolli
Christine Brotschi
Cyrille Lescop
Jodi T. Williams
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of HRP20230243T1 publication Critical patent/HRP20230243T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HRP20230243TT 2018-06-07 2019-06-05 Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze HRP20230243T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2018065016 2018-06-07
PCT/EP2019/064690 WO2019234115A1 (en) 2018-06-07 2019-06-05 Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis
EP19731163.2A EP3802517B1 (en) 2018-06-07 2019-06-05 Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis

Publications (1)

Publication Number Publication Date
HRP20230243T1 true HRP20230243T1 (hr) 2023-04-14

Family

ID=66912779

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230243TT HRP20230243T1 (hr) 2018-06-07 2019-06-05 Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze

Country Status (22)

Country Link
US (1) US12344597B2 (enExample)
EP (1) EP3802517B1 (enExample)
JP (1) JP7386183B2 (enExample)
KR (1) KR102826034B1 (enExample)
CN (1) CN112236424B (enExample)
AU (1) AU2019282274A1 (enExample)
BR (1) BR112020024879A2 (enExample)
CA (1) CA3102683A1 (enExample)
DK (1) DK3802517T3 (enExample)
EA (1) EA202092955A1 (enExample)
ES (1) ES2940695T3 (enExample)
FI (1) FI3802517T3 (enExample)
HR (1) HRP20230243T1 (enExample)
HU (1) HUE061559T2 (enExample)
LT (1) LT3802517T (enExample)
MX (1) MX2020013291A (enExample)
PL (1) PL3802517T3 (enExample)
PT (1) PT3802517T (enExample)
RS (1) RS63990B1 (enExample)
SI (1) SI3802517T1 (enExample)
TW (1) TW202016090A (enExample)
WO (1) WO2019234115A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119162A1 (es) * 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
WO2021110805A1 (en) * 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
FI20225388A1 (en) * 2022-05-05 2023-11-06 Equinorm Ltd New heterocyclic compounds, preparation methods and their uses
WO2025169931A1 (ja) * 2024-02-05 2025-08-14 Ube株式会社 カルボキサミド化合物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (enExample) 1960-03-14
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AU7961300A (en) 1999-10-29 2001-05-14 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
EP1364659B1 (en) 2001-02-08 2009-11-11 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
CN102584813B (zh) 2003-05-14 2016-07-06 Ngc药物公司 化合物及其在调节淀粉样蛋白β中的用途
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
WO2005037269A1 (ja) 2003-10-21 2005-04-28 Dainippon Sumitomo Pharma Co., Ltd. 新規ピペリジン誘導体
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
TWI377198B (en) 2005-08-24 2012-11-21 Eisai R&D Man Co Ltd Novel pyridine derivatives and pyrimidine derivatives (3)
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
EP2035005A4 (en) 2006-06-09 2011-07-06 Kemia Inc THERAPY BASED ON CYTOKINE INHIBITORS
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
AU2008311971A1 (en) 2007-10-18 2009-04-23 Merck Sharp & Dohme Corp. Quinolizidinone M1 receptor positive allosteric modulators
EP2297153B1 (en) 2008-04-21 2015-05-27 Lexicon Pharmaceuticals, Inc. Limk2 inhibitors, compositions comprising them, and methods of their use
AU2009243756B2 (en) 2008-05-05 2013-06-27 Sanofi-Aventis Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals
BRPI0918971A2 (pt) 2008-08-26 2015-12-01 Boehringer Ingelheim Int tienopirimidinas para composições farmacêuticas
JP5708936B2 (ja) 2009-09-25 2015-04-30 アステラス製薬株式会社 置換アミド化合物
ES2682303T3 (es) 2010-08-05 2018-09-19 Zoetis Services Llc Derivados de isoxazolina como agentes antiparasitarios
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為mPGES-1抑制物的三環化合物
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
PT2683723T (pt) 2011-03-10 2016-08-05 Zoetis Services Llc Derivados espirocíclicos de isoxazolina como agentes antiparasitários
JP2015506349A (ja) 2011-12-21 2015-03-02 アルデリックス, インコーポレイテッド 非全身性tgr5アゴニスト
WO2014079805A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶cdk9激酶抑制劑
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
AR119162A1 (es) 2019-06-18 2021-12-01 Idorsia Pharmaceuticals Ltd Derivados de piridin-3-ilo
WO2021110805A1 (en) 2019-12-04 2021-06-10 Idorsia Pharmaceuticals Ltd Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases

Also Published As

Publication number Publication date
KR102826034B1 (ko) 2025-06-27
KR20210018900A (ko) 2021-02-18
CN112236424A (zh) 2021-01-15
BR112020024879A2 (pt) 2021-03-09
CA3102683A1 (en) 2019-12-12
WO2019234115A1 (en) 2019-12-12
JP7386183B2 (ja) 2023-11-24
AU2019282274A1 (en) 2021-01-28
EA202092955A1 (ru) 2021-04-08
FI3802517T3 (fi) 2023-03-23
PL3802517T3 (pl) 2023-05-22
US12344597B2 (en) 2025-07-01
US20210246116A1 (en) 2021-08-12
TW202016090A (zh) 2020-05-01
CN112236424B (zh) 2024-03-15
LT3802517T (lt) 2023-03-10
EP3802517B1 (en) 2022-12-21
MX2020013291A (es) 2021-04-29
ES2940695T3 (es) 2023-05-10
RS63990B1 (sr) 2023-03-31
JP2021527046A (ja) 2021-10-11
HUE061559T2 (hu) 2023-07-28
EP3802517A1 (en) 2021-04-14
PT3802517T (pt) 2023-03-20
DK3802517T3 (da) 2023-03-13
SI3802517T1 (sl) 2023-04-28

Similar Documents

Publication Publication Date Title
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
RU2021133444A (ru) Производные бензимидазола в качестве модуляторов ror-гамма
JP2017530999A5 (enExample)
JP2016519156A5 (enExample)
JP2019077725A5 (enExample)
HRP20161011T1 (hr) Aril dihidropiridinoni i piperidinoni kao inhibitori mgat2
JP2021527046A5 (enExample)
RU2017116197A (ru) 2-амино-3,5-дифтор-3,6-диметил-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 для лечения болезни альцгеймера
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
RU2008126398A (ru) Производные гетероарилзамещенного пиперидина в качестве ингибиторов печеночной карнитин пальмитоилтрансферазы (l-cpti)
HRP20150355T1 (hr) Sulfonamidni derivati
HRP20170112T1 (hr) Supstituirani spojevi piridin-2-karboksamida kao kinazni inhibitori signalne regulacije apoptoze
HRP20160421T1 (hr) Derivat azola
JP2012525349A5 (enExample)
WO2015008230A1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
RU2015154987A (ru) Гетероциклические производные
HRP20160678T1 (hr) Derivati 2-(1,2,3-triazol-2-il)benzamida i 3-(1,2,3-triazol-2-il)pikolinamida kao antagonisti receptora oreksina
JP2017518961A5 (enExample)
ME00427B (me) N-supstituisani hidroksipiramidinon karboksamidni inhibitori hiv integraze
JP2015501799A5 (enExample)
JP2016503009A5 (enExample)
JP2008517945A5 (enExample)
FI3802517T3 (fi) Alkoksisubstituoituja pyridinyylijohdannaisia LPA1-reseptoriantagonisteina ja niiden käyttö fibroosin hoidossa
RU2010106974A (ru) Ариловые эфиры пирролидина в качестве антагонистов рецепторов nk3
JP2014521696A5 (enExample)